Firstly, we will employ CRISPR to disrupt PTGDS in organoids derived from patients and co-culture them with autologous macrophages to simulate tumor-immune interactions in a physiological setting and elucidate the impact of PI3K/AKT modulation[4]. The gene discussed is AKT1; the disease is neoplasm.